Page 24 - Cipla

Cipla sharpens focus on core therapies

Cipla, the pharmaceuticals major, is exiting non-core businesses to build a stronger pipeline in its key therapies on offer, of respiratory, oncology and anti-HIV drugs. This comes at a time when it faces pricing pressure in both India and America. The move will mean more capital for key growth areas and reduce investment risk.One step is the decision to scale down the biotechnology business. Last week, Cipla said it would not manufacture biosimilars. It also put on hold an earlier plan for a manufacturing unit in South Africa. The announcement was made after a Rs 62 crore loss in the March quarter.It is, however, not exiting the biotech segment. It will look for in-licensing opportunities and partners for two biosimilar drugs which are under trial.Umang Vohra, chief executive officer, said they now aimed to strengthen business in the core markets (India, the US and South Africa) and core therapies such as respiratory, oncology and anti-HIV drugs. "You will see us doing lot more in ...

Weak domestic sales hurt Cipla in Q4

Sales from this segment account for the largest share in revenue

Margin expansion crucial for Cipla's stock

Cipla continues to strengthen its global footprint. Wednesday's acquisition of Anmarate (Pty) Ltd in South Africa, and Cipla USA entering into a collaboration with MEDRx a few days ago, are a step in this direction. Such moves will help Cipla report healthy topline growth, but analysts say improvement in profitability is equally crucial.The acquisition of Anmarate, which develops and manufactures medicines and medical devices, will add to Cipla's strengths in South Africa, which already contributes about 13 per cent to its revenues. The US collaboration is to take further the development and commercialisation of MRX-4TZT, a tizanidine1 patch for the management of spasticity. This will enhance Cipla's presence in branded specialty space. To bolster the US generic business, Cipla has already completed two acquisitions last year. It is also on course for achieving full year guidance of 20-25 ANDAs (abbreviated new drug applications) having already filed 21 ANDAs during first nine months .

Delhi HC upholds order restricting sale of Cipla's respiratory disease drug

Cipla's Unibrez costs Rs 130 per pack of ten tablets, compared with Rs 677 for Onbrez

Cipla sells South African animal health biz to Ascendis for Rs 190 cr

With this move, the company will completely exit its animal health care business in the country

Cipla to enter Brazil, China with emerging market focus

Furthering a strategy of expanding in India, South Africa and US markets

Cipla's Q3 net profit jumps by 44% to Rs 375 cr

Net sales during the quarter under review stood at Rs 3,550.02 crore

Cipla gets UK nod to sell key inhaler for asthmatics

Firm's Sereflo inhaler is a generic version of GSK's Advair, has a market size of $278 mn in Britain

Cipla up 5% on UK MHRA approval for generic asthma drug

The stock gained 5% to Rs 589, bouncing back 6.5% from intra-day low on the BSE

Cipla sells 16.7% stake in Chase Pharma to Allergan

Cipla UK had acquired a minority stake in Chase in May 2014 via a syndicated venture investment

Cipla plans to get more aggressive in US, UK

The market size for blockbuster inhaler Seretide in Britain was $400 million last year, say analysts

Cipla Q2 profit falls as Europe, emerging markets suffer

Sales in India, Cipla's biggest market, rose 21% in the quarter

Cipla is back to old strategy with a twist

US likely to bring significant growth

Blow to Cipla; company loses court battle in drug-overcharging case

Company had received notices of demand aggregating to Rs 1,768 cr

Cipla signs deal to set up first biosimilars unit in South Africa

The agreement with KwaZulu-Natal Dube Trade Port SEZ for Cipla BIOTEC's new facility was concluded during the BRICS Summit

Cipla gains as Indore plant gets US FDA clearance

The stock was up 3% to Rs 596 on the BSE in early morning trade.

Cipla's Indore plant cleared by FDA

The clearance indicates the formal closure of the US FDA inspection conducted in July/August, 2015

Concerns aggravate for Cipla, Alkem

More worries for Alkem, as its Daman plant, which is under scanner, is crucial for US growth

Cipla falls on heavy volumes

The stock dipped 6% to Rs 562 in intra-day trade on media reports that the USFDA inspected the company's Goa facility.

Drug firms facing challenging times due to price control: Cipla

Tightening of new product registration procedures also impacting industry